Companies › Pierre Fabre Medicament
7 active drug programs in 35 registered trials: 24 Phase 2, 8 Phase 1, 3 Phase 3; Oncology, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Binimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Melanoma; Non-Small Cell Lung Cancer; Solid Tumor, Adult; Solid Tumor … | Dec 2026 |
| Encorafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 3 | Melanoma; Non-Small Cell Lung Cancer | Dec 2026 |
| tabelecleucel Allogeneic EBV-specific T-cell immunotherapy | – | Phase 3 | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Epstein-Barr Virus (EBV)-Associated Diseases | Jun 2027 |
| STX-241 Mutant-selective CNS-penetrant fourth generation EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Nov 2027 |
| KIN-2787 BRAF inhibitor | BRAF | Phase 1 | Solid Tumor, Adult | Nov 2028 |
| STX-721/PFL-721 Exon 20 insertion-selective tyrosine kinase inhibitor | EGFR, HER2 | Phase 1 | Non-Small Cell Lung Cancer | Dec 2029 |
| VERT-002 MET inhibitor | MET | Phase 1 | Solid Tumor | Oct 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01991379 | Binimetinib | Phase 1 | Gastrointestinal Stromal Tumor (GIST) | Oncology | Nov 2026 |
| NCT05195632 | Encorafenib | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05195632 | Binimetinib | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT03839342 | Binimetinib | Phase 2 | Solid Tumor | Oncology | Dec 2026 |
| NCT03991819 | Binimetinib | Phase 1 | Non-small Cell Carcinoma | Oncology | Dec 2026 |
| NCT03971409 | Binimetinib | Phase 2 | Stage III Breast Cancer | Oncology | Jan 2027 |
| NCT05026983 | Binimetinib | Phase 2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Oncology | Feb 2027 |
| NCT06159478 | Binimetinib | Phase 2 | Low-grade Glioma | Oncology | Feb 2027 |
| NCT05111561 | Binimetinib | Phase 1 | Advanced Malignant Solid Neoplasm | Oncology | Mar 2027 |
| NCT04526782 | Binimetinib | Phase 2 | Non Small Cell Lung Cancer | Oncology | Mar 2027 |
| NCT04074096 | Binimetinib | Phase 2 | Malignant Melanoma | Oncology | Mar 2027 |
| NCT05270044 | Encorafenib | Phase 3 | Melanoma | Oncology | Mar 2027 |
| NCT05270044 | Binimetinib | Phase 3 | Melanoma | Oncology | Mar 2027 |
| NCT04439344 | Binimetinib | Phase 2 | Advanced Lymphoma | Oncology | Mar 2027 |
| NCT05286788 | Binimetinib | Phase 2 | Adamantinous Craniopharyngioma | Oncology | Apr 2027 |
| NCT04554914 | tabelecleucel | Phase 2 | Epstein-Barr Virus (EBV)-Associated Diseases | Oncology | Jun 2027 |
| NCT04511013 | Binimetinib | Phase 2 | Acral Lentiginous Melanoma | Oncology | Jun 2027 |
| NCT05564403 | Binimetinib | Phase 2 | Advanced Biliary Tract Carcinoma | Oncology | Oct 2027 |
| NCT06567015 | STX-241 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Nov 2027 |
| NCT02910700 | Binimetinib | Phase 2 | Metastatic Malignant Neoplasm in the Brain | Oncology | Dec 2027 |
| NCT04061980 | Binimetinib | Phase 2 | BRAF NP_004324.2:p.V600M | Oncology | Dec 2027 |
| NCT02465060 | Binimetinib | Phase 2 | Advanced Lymphoma | Oncology | Dec 2027 |
| NCT06887088 | Binimetinib | Phase 2 | Melanoma BRAF V600E/K Mutated | Oncology | Jan 2028 |
| NCT05170334 | Binimetinib | Phase 2 | Metastatic Uveal Melanoma | Oncology | Jan 2028 |
| NCT04322383 | Binimetinib | Phase 2 | Hairy Cell Leukemia | Oncology | Apr 2028 |
| NCT05097378 | Binimetinib | Phase 2 | Melanoma | Oncology | May 2028 |
| NCT05554367 | Binimetinib | Phase 2 | Exocrine Pancreas Carcinoma | Oncology | Aug 2028 |
| NCT04913285 | Binimetinib | Phase 1 | Solid Tumor, Adult | Oncology | Nov 2028 |
| NCT04913285 | KIN-2787 | Phase 1 | Solid Tumor, Adult | Oncology | Nov 2028 |
| NCT06207656 | Binimetinib | Phase 2 | Colorectal Cancer | Oncology | Apr 2029 |
| NCT04324112 | Binimetinib | Phase 2 | Hairy Cell Leukemia | Oncology | Jun 2029 |
| NCT06043817 | STX-721/PFL-721 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Dec 2029 |
| NCT03394365 | tabelecleucel | Phase 3 | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Infectious disease | May 2030 |
| NCT05564377 | Binimetinib | Phase 2 | Advanced Malignant Solid Neoplasm | Oncology | Jul 2030 |
| NCT06669117 | VERT-002 | Phase 1 | Solid Tumor | Oncology | Oct 2030 |
Jiangsu Alphamab Biopharmaceuticals Shanghai Kechow Pharma Avistone Biotechnology Nanjing Sanhome Pharmaceutical Hansoh BioMedical R&D Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.